scholarly journals 345: Is it worth it? A cost-savings analysis of telemedicine care in a cystic fibrosis population

2021 ◽  
Vol 20 ◽  
pp. S165-S166
Author(s):  
J. Patel ◽  
M. Isenberg ◽  
J. McKinney ◽  
J. Spahr
Keyword(s):  
Cystic Fibrosis ◽  
Cost Savings ◽  
Cystic Fibrosis Population

ΔF508 Genotype Does Not Predict Disease Severity in an Ethnically Diverse Cystic Fibrosis Population

PEDIATRICS ◽  
1994 ◽  
Vol 93 (1) ◽  
pp. 114-118
Author(s):  
Lucille A. Lester ◽  
Jerome Kraut ◽  
John Lloyd-Still ◽  
Theodore Karrison ◽  
Carol Mott ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Disease Severity ◽  
Ethnically Diverse ◽  
Clinical Parameter ◽  
Population Based ◽  
Age At Diagnosis ◽  
Chest Roentgenogram ◽  
Sweat Chloride ◽  
Cystic Fibrosis Population ◽  
Cftr Mutations

Objective. As part of a study to determine population-based frequencies of CFTR mutations in an ethnically diverse, midwestern cystic fibrosis (CF) population, clinical histories were studied in 119 CF patients. Methodology. We sought to examine the association between genotype as characterized by the ΔF508 and 11 other commonly occurring mutations and clinical parameters including age at diagnosis, clinical presentation, sweat chloride level, chest roentgenogram score, clinical scores, pulmonary function test results, percent weight for height, and presence of associated CF complications. Results. Age at diagnosis of CF was significantly associated with homozygosity for ΔF508 (mean age at diagnosis ± SE: 1.7 ± 0.3 years for ΔF508/ΔF508 vs 3.9 ± 0.9 years for ΔF508/other and other/other; P = .03). No other age-adjusted clinical parameter was significantly associated with ΔF508 or any other genotype. Conclusion. These data suggest that in this sample of CF patients, ΔF508 genotype is not predictive of disease severity. The lack of association between disease severity and genotype in this ethnically diverse sample may reflect the presence of more severe undetected mutations in our sample, or the effects of modifying genes at other, non-CF loci.

Cost of therapy for cystic fibrosis in different age groups with consideration to the respiratory tract infection and complications

2021 ◽  
Vol 31 (2) ◽  
pp. 238-249
Author(s):  
E. G. Furman ◽  
V. V. Shadrina ◽  
T. Yu. Maksimycheva ◽  
V. D. Sherman ◽  
E. I. Kondratyeva
Keyword(s):  
Cystic Fibrosis ◽  
Respiratory Tract ◽  
Pharmacoeconomic Analysis ◽  
Age Groups ◽  
Eradication Therapy ◽  
Cost Savings ◽  
Hypothetical Patient ◽  
Severity Of The Disease ◽  
Cost Of Drugs ◽  
The Cost

Despite the low prevalence of cystic fibrosis (CF), the costs of treating this disease are significant for the healthcare system. The aim of this economic study was to assess the total cost of drugs per year for children with CF, depending on age and course of the disease.Methods. For this pharmacoeconomic analysis, groups of “hypothetical” patients were formed according to the characteristics of the course of CF, taking into account the required volume of basic CF therapy, antibiotic therapy, and complications.Results. The cost of basic treatment for CF patients of different ages and disease progression in the hypothetical patient models can vary greatly. The cost of CF therapy increases significantly with age and Pseudomonas aeruginosa respiratory infection, especially in the patients with chronic infection, concomitant polyposis sinusitis, and low nutritional status.Conclusion. Patients with CF require regular follow-up with control of the microflora of the respiratory tract and effective eradication therapy for P. aeruginosa and other pathogenic microorganisms. Reducing infection rates and the severity of the disease can lead to significant cost savings.

scholarly journals 42 Microbiologic bacterial agents in a young cystic fibrosis population

2015 ◽  
Vol 14 ◽  
pp. S68
Author(s):  
A.C. Freitas ◽  
J.O. Neves ◽  
T. Barbosa ◽  
V. Lopes ◽  
H. Ramos ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Cystic Fibrosis Population

scholarly journals Renal impairment in the adult cystic fibrosis population

2008 ◽  
Vol 7 ◽  
pp. S87
Author(s):  
S.J. King ◽  
C. De Clercq ◽  
D.J. Topliss ◽  
N. Thomson ◽  
J.W. Wilson
Keyword(s):  
Cystic Fibrosis ◽  
Renal Impairment ◽  
Cystic Fibrosis Population

scholarly journals Once Daily Dosing of Aminoglycosides in Pediatric Cystic Fibrosis Patients: A Review of the Literature

2008 ◽  
Vol 13 (2) ◽  
pp. 68-75
Author(s):  
Sarah K. Wassil ◽  
Kristie M. Fox ◽  
James W. White
Keyword(s):  
Cystic Fibrosis ◽  
Review Of The Literature ◽  
Nursing Time ◽  
Once Daily ◽  
Development Of Resistance ◽  
Cystic Fibrosis Population ◽  
Antibiotic Effect ◽  
Home Administration ◽  
Post Antibiotic Effect

Patients with cystic fibrosis receive many courses of antibiotic therapy throughout their lifetime. Dosing aminoglycosides once daily has become common practice in many of these individuals. Due to ease of home administration, decreased nursing time, and improved quality of life, this regimen is being increasingly explored in the cystic fibrosis population. Because patients with cystic fibrosis have increased aminoglycoside clearance, once daily dosing may result in a prolonged time during the dosing interval when concentrations of the drug may be undetectable. This makes the use of once daily dosing of these antibiotics in patients with cystic fibrosis controversial. Although aminoglycosides exhibit a post antibiotic effect, the duration of this effect is unknown in humans; therefore, the development of resistance to the aminoglycoside is a concern. This manuscript will review the organisms most commonly associated with a pulmonary exacerbation of cystic fibrosis, the properties of the aminoglycoside that make once daily dosing feasible, the concept of once daily dosing in those with cystic fibrosis and the current literature regarding efficacy, monitoring, toxicity and concerns of resistance with once daily dosing in this population.

scholarly journals Epidemiology of cystic fibrosis respiratory pathogens isolated at a South African Hospital, 2006–2010

2016 ◽  
Vol 31 (4) ◽  
pp. 106-111
Author(s):  
Vindana Chibabhai ◽  
Warren Lowman
Keyword(s):  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
South African ◽  
Burkholderia Cepacia ◽  
Stenotrophomonas Maltophilia ◽  
Burkholderia Cepacia Complex ◽  
Respiratory Pathogens ◽  
Academic Hospital ◽  
Cystic Fibrosis Population ◽  
Susceptibility Patterns

Background: The epidemiology of cystic fibrosis (CF) associated pathogens other than Pseudomonas aeruginosa in the South African cystic fibrosis population has not been previously described.Methods: A retrospective review of respiratory cultures taken from cystic fibrosis clinic patients at the Charlotte Maxeke Johannesburg Academic Hospital from 2006 to 2010 was performed.Results: During the study period, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cepacia complex and Candida albicans prevalence remained stable, Aspergillus fumigatus increased from 8% to 20% (p = 0.0132); Staphylococcus aureus decreased from 66% to 50% (p = 0.0243) and Haemophilus influenzae decreased from 13% to 3% (p = 0.0136). There were significant antimicrobial susceptibility changes to meropenem (p  0.0001) amongst P. aeruginosa isolates and cloxacillin (p 0.0001) amongst S. aureus isolates. Prevalence of most bacterial pathogens appeared to increase with increasing age.Conclusion: The findings of this study illustrate the epidemiology of CF associated respiratory pathogens and the trends in prevalence and susceptibility patterns over a 5-year period.

Sign in / Sign up

Export Citation Format

Share Document